Critical Comparison: Oncobiologics (OTLK) versus Its Peers

Oncobiologics (NASDAQ:OTLK) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Oncobiologics to related businesses based on the strength of its analyst recommendations, profitability, valuation, earnings, dividends, risk and institutional ownership.

Earnings & Valuation

This table compares Oncobiologics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncobiologics	$1.35 million	-$62.42 million	-0.60
Oncobiologics Competitors	$698.08 million	$10.43 million	-15.43

Oncobiologics’ rivals have higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 1.8% of Oncobiologics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Oncobiologics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1	2	2	0	2.20
Oncobiologics Competitors	9839	15126	45471	1588	2.54

Oncobiologics currently has a consensus target price of $5.20, suggesting a potential upside of 1,032.16%. As a group, “Biotechnology” companies have a potential upside of 98.28%. Given Oncobiologics’ higher probable upside, equities analysts clearly believe Oncobiologics is more favorable than its rivals.

Profitability

This table compares Oncobiologics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Oncobiologics Competitors	-12,359.35%	-203.09%	-30.93%

Risk and Volatility

Oncobiologics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Oncobiologics’ rivals have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.

Summary

Oncobiologics rivals beat Oncobiologics on 9 of the 12 factors compared.

Oncobiologics Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.